11
Nov 2026
Experimental drug targets tumor barriers to unlock cancer-killing T cells
Many solid tumors, including many cancers of the pancreas, breast, brain and lung, protect themselves with a dense wall of scar-like tissue.
11
Nov 2026
Many solid tumors, including many cancers of the pancreas, breast, brain and lung, protect themselves with a dense wall of scar-like tissue.
11
Nov 2026
A new peer-reviewed review in Psychedelics opens on a strange fact, gathered from existing laboratory studies rather than new experiments: a brain tumor can learn to eavesdrop.
11
Nov 2026
"Eat less, live longer" has a firm footing in the laboratory: dietary restriction extends lifespan across species, from yeast to mammals.
11
Nov 2026
Yourgene Health (part of the Novacyt Group), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces Australian regulatory approval for its Yourgene® Insight DPYD assay.
11
Nov 2026
T-Cypher Bio ("T-Cypher), a biotechnology company developing novel T cell receptor (TCR)-based T cell engagers that target high copy number antigens, today announced its relocation to Abingdon Science Park, Oxford, UK.
11
Nov 2026
Mogrify Limited (Mogrify®), a regenerative medicine company developing a novel class of in vivo reprogramming therapies, today announced it will present preclinical proof-of-concept data at FLORetina-ICOOR 2026.
11
Nov 2026
Findings suggest omega-3 supplements improve blood pressure and inflammatory biomarkers in hypertensive patients, indicating potential therapeutic benefits.
11
Nov 2026
The challenge for India’s pharmaceutical manufacturers is clear: How to reliably scale production, reduce energy costs, and safeguard operators – all at once. From November 24 to 26, 2026, L.B. Bohle will present these solutions at stand 9C02 in the India Expo Centre & Mart (IEML) in Greater Noida.
10
Nov 2026
Losing a job can be a life-shattering experience. And when depression complicates a job search, unemployment can become a vicious cycle.
10
Nov 2026
The European Innovation Council (EIC) is providing approximately €3.8 million in funding for the international research project ADVANCE, in which Universitätsmedizin Frankfurt is participating. The ADVANCE research team aims to develop an mRNA-based cancer vaccine for the treatment of hepatocellular carcinoma (HCC).
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more